De Burlo Group Inc Concert Pharmaceuticals, Inc. Transaction History

De Burlo Group Inc

  • $808 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.27 - $7.2 $853 - $1,440
200 New
200 $0
Q2 2022

Aug 11, 2022
SELL
$2.8 - $6.36 $560 - $1,272
-200 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$2.73 - $3.94 $546 - $788
200 New
200 $0

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About CONCERT PHARMACEUTICALS, INC.

CNCE Quotes by TradingView
  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track De Burlo Group Inc Portfolio

Follow De Burlo Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of De Burlo Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on De Burlo Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email